Eintrag weiter verarbeiten
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours
Gespeichert in:
| Zeitschriftentitel: | ANZ Journal of Surgery |
|---|---|
| Personen und Körperschaften: | , |
| In: | ANZ Journal of Surgery, 72, 2002, 9, S. 635-638 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Rohaizak, Muhammad Farndon, John Richard Rohaizak, Muhammad Farndon, John Richard |
|---|---|
| author |
Rohaizak, Muhammad Farndon, John Richard |
| spellingShingle |
Rohaizak, Muhammad Farndon, John Richard ANZ Journal of Surgery Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours General Medicine Surgery |
| author_sort |
rohaizak, muhammad |
| spelling |
Rohaizak, Muhammad Farndon, John Richard 1445-1433 1445-2197 Wiley General Medicine Surgery http://dx.doi.org/10.1046/j.1445-2197.2002.02507.x <jats:p> <jats:bold>Background:</jats:bold> Carcinoid tumours are rare neoplasms that secrete hormones and biogenic amines, most commonly serotonin. Octreotide and long acting lanreotide are found to be useful in the management of carcinoid syndrome by its interaction with somatostatin receptor, found on the carcinoid tumour. The aim of this study is to look at the efficacy of octreotide and long acting lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p> <jats:bold>Method:</jats:bold> The effects of octreotide and long‐acting lanreotide were studied in 10 patients with symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p> <jats:bold>Results:</jats:bold> Symptom improvement occurred in nine of 10 patients. Three patients responded only to octreotide, three patients responded to both octreotide and long‐acting lanreotide and three patients only responded to long‐acting lanreotide. Slight reductions in 24‐h urine 5‐hydroxyindoleacetic acid levels occurred in three of six patients but no patients were found to have objective tumour regression on computed tomography scan.</jats:p><jats:p> <jats:bold>Conclusions:</jats:bold> Octreotide and long‐acting lanreotide are useful palliative treatments for the control of symptoms in patients with non‐resectable carcinoid tumours but there is no evidence of tumour stasis.</jats:p> Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours ANZ Journal of Surgery |
| doi_str_mv |
10.1046/j.1445-2197.2002.02507.x |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjE0NDUtMjE5Ny4yMDAyLjAyNTA3Lng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjE0NDUtMjE5Ny4yMDAyLjAyNTA3Lng |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 |
| imprint |
Wiley, 2002 |
| imprint_str_mv |
Wiley, 2002 |
| issn |
1445-2197 1445-1433 |
| issn_str_mv |
1445-2197 1445-1433 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
rohaizak2002useofoctreotideandlanreotideinthetreatmentofsymptomaticnonresectablecarcinoidtumours |
| publishDateSort |
2002 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
ANZ Journal of Surgery |
| source_id |
49 |
| title |
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_unstemmed |
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_full |
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_fullStr |
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_full_unstemmed |
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_short |
Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_sort |
use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| topic |
General Medicine Surgery |
| url |
http://dx.doi.org/10.1046/j.1445-2197.2002.02507.x |
| publishDate |
2002 |
| physical |
635-638 |
| description |
<jats:p>
<jats:bold>Background:</jats:bold> Carcinoid tumours are rare neoplasms that secrete hormones and biogenic amines, most commonly serotonin. Octreotide and long acting lanreotide are found to be useful in the management of carcinoid syndrome by its interaction with somatostatin receptor, found on the carcinoid tumour. The aim of this study is to look at the efficacy of octreotide and long acting lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p>
<jats:bold>Method:</jats:bold> The effects of octreotide and long‐acting lanreotide were studied in 10 patients with symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p>
<jats:bold>Results:</jats:bold> Symptom improvement occurred in nine of 10 patients. Three patients responded only to octreotide, three patients responded to both octreotide and long‐acting lanreotide and three patients only responded to long‐acting lanreotide. Slight reductions in 24‐h urine 5‐hydroxyindoleacetic acid levels occurred in three of six patients but no patients were found to have objective tumour regression on computed tomography scan.</jats:p><jats:p>
<jats:bold>Conclusions:</jats:bold> Octreotide and long‐acting lanreotide are useful palliative treatments for the control of symptoms in patients with non‐resectable carcinoid tumours but there is no evidence of tumour stasis.</jats:p> |
| container_issue |
9 |
| container_start_page |
635 |
| container_title |
ANZ Journal of Surgery |
| container_volume |
72 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341518080540673 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:21:11.028Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Use+of+octreotide+and+lanreotide+in+the+treatment+of+symptomatic+non%E2%80%90resectable+carcinoid+tumours&rft.date=2002-09-01&genre=article&issn=1445-2197&volume=72&issue=9&spage=635&epage=638&pages=635-638&jtitle=ANZ+Journal+of+Surgery&atitle=Use+of+octreotide+and+lanreotide+in+the+treatment+of+symptomatic+non%E2%80%90resectable+carcinoid+tumours&aulast=Farndon&aufirst=John+Richard&rft_id=info%3Adoi%2F10.1046%2Fj.1445-2197.2002.02507.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341518080540673 |
| author | Rohaizak, Muhammad, Farndon, John Richard |
| author_facet | Rohaizak, Muhammad, Farndon, John Richard, Rohaizak, Muhammad, Farndon, John Richard |
| author_sort | rohaizak, muhammad |
| container_issue | 9 |
| container_start_page | 635 |
| container_title | ANZ Journal of Surgery |
| container_volume | 72 |
| description | <jats:p> <jats:bold>Background:</jats:bold> Carcinoid tumours are rare neoplasms that secrete hormones and biogenic amines, most commonly serotonin. Octreotide and long acting lanreotide are found to be useful in the management of carcinoid syndrome by its interaction with somatostatin receptor, found on the carcinoid tumour. The aim of this study is to look at the efficacy of octreotide and long acting lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p> <jats:bold>Method:</jats:bold> The effects of octreotide and long‐acting lanreotide were studied in 10 patients with symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p> <jats:bold>Results:</jats:bold> Symptom improvement occurred in nine of 10 patients. Three patients responded only to octreotide, three patients responded to both octreotide and long‐acting lanreotide and three patients only responded to long‐acting lanreotide. Slight reductions in 24‐h urine 5‐hydroxyindoleacetic acid levels occurred in three of six patients but no patients were found to have objective tumour regression on computed tomography scan.</jats:p><jats:p> <jats:bold>Conclusions:</jats:bold> Octreotide and long‐acting lanreotide are useful palliative treatments for the control of symptoms in patients with non‐resectable carcinoid tumours but there is no evidence of tumour stasis.</jats:p> |
| doi_str_mv | 10.1046/j.1445-2197.2002.02507.x |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjE0NDUtMjE5Ny4yMDAyLjAyNTA3Lng |
| imprint | Wiley, 2002 |
| imprint_str_mv | Wiley, 2002 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161 |
| issn | 1445-2197, 1445-1433 |
| issn_str_mv | 1445-2197, 1445-1433 |
| language | English |
| last_indexed | 2024-03-01T16:21:11.028Z |
| match_str | rohaizak2002useofoctreotideandlanreotideinthetreatmentofsymptomaticnonresectablecarcinoidtumours |
| mega_collection | Wiley (CrossRef) |
| physical | 635-638 |
| publishDate | 2002 |
| publishDateSort | 2002 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | ANZ Journal of Surgery |
| source_id | 49 |
| spelling | Rohaizak, Muhammad Farndon, John Richard 1445-1433 1445-2197 Wiley General Medicine Surgery http://dx.doi.org/10.1046/j.1445-2197.2002.02507.x <jats:p> <jats:bold>Background:</jats:bold> Carcinoid tumours are rare neoplasms that secrete hormones and biogenic amines, most commonly serotonin. Octreotide and long acting lanreotide are found to be useful in the management of carcinoid syndrome by its interaction with somatostatin receptor, found on the carcinoid tumour. The aim of this study is to look at the efficacy of octreotide and long acting lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p> <jats:bold>Method:</jats:bold> The effects of octreotide and long‐acting lanreotide were studied in 10 patients with symptomatic non‐resectable carcinoid tumours.</jats:p><jats:p> <jats:bold>Results:</jats:bold> Symptom improvement occurred in nine of 10 patients. Three patients responded only to octreotide, three patients responded to both octreotide and long‐acting lanreotide and three patients only responded to long‐acting lanreotide. Slight reductions in 24‐h urine 5‐hydroxyindoleacetic acid levels occurred in three of six patients but no patients were found to have objective tumour regression on computed tomography scan.</jats:p><jats:p> <jats:bold>Conclusions:</jats:bold> Octreotide and long‐acting lanreotide are useful palliative treatments for the control of symptoms in patients with non‐resectable carcinoid tumours but there is no evidence of tumour stasis.</jats:p> Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours ANZ Journal of Surgery |
| spellingShingle | Rohaizak, Muhammad, Farndon, John Richard, ANZ Journal of Surgery, Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours, General Medicine, Surgery |
| title | Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_full | Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_fullStr | Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_full_unstemmed | Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_short | Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_sort | use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| title_unstemmed | Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours |
| topic | General Medicine, Surgery |
| url | http://dx.doi.org/10.1046/j.1445-2197.2002.02507.x |